Literature DB >> 28451698

[Still's disease in children and adults].

C M Hedrich1, C Günther2, M Aringer3.   

Abstract

Systemic juvenile idiopathic arthritis (sJIA) is characterized by fever, arthritis, and other signs of systemic inflammation. Historically, sJIA was named Still's disease after George Frederic Still, who first reported patients. Individuals who manifest after the 16th birthday are diagnosed with adult onset Still's disease (AOSD). The pathophysiology of sJIA and AOSD are incompletely understood. Increased activation of inflammasomes and the expression of proinflammatory cytokines play a central role. S100 proteins, which can activate Toll-like receptors, thus, maintaining positive feedback loops, have also been detected at increased levels in sera from sJIA patients. Reduced expression of the immune-modulatory cytokine IL-10 may further contribute to immune cell activation and the production of proinflammatory molecules. Here, we discuss the clinical picture, differential diagnoses, the current pathophysiological understanding, and treatment options in sJIA and AOSD.

Entities:  

Keywords:  Adult onset Still’s disease; Cytokines; Inflammasome; Systemic juvenile idiopathic arthritis; Treatment

Mesh:

Substances:

Year:  2017        PMID: 28451698     DOI: 10.1007/s00105-017-3983-7

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  85 in total

Review 1.  Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches.

Authors:  Normi Bruck; Anja Schnabel; Christian M Hedrich
Journal:  Clin Immunol       Date:  2015-05-06       Impact factor: 3.969

2.  A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.

Authors:  Raphaela Goldbach-Mansky; Sharukh D Shroff; Mildred Wilson; Christopher Snyder; Sara Plehn; Beverly Barham; Tuyet-Hang Pham; Frank Pucino; Robert A Wesley; Joanne H Papadopoulos; Steven P Weinstein; Scott J Mellis; Daniel L Kastner
Journal:  Arthritis Rheum       Date:  2008-08

3.  Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study.

Authors:  Wilco de Jager; Esther P A H Hoppenreijs; Nico M Wulffraat; Lucy R Wedderburn; Wietse Kuis; Berent J Prakken
Journal:  Ann Rheum Dis       Date:  2006-12-14       Impact factor: 19.103

4.  IL10 promoter polymorphisms are associated with systemic onset juvenile idiopathic arthritis (SoJIA).

Authors:  J C Möller; D Paul; G Ganser; U Range; M Gahr; R Kelsch; A Rösen-Wolff; C M Hedrich
Journal:  Clin Exp Rheumatol       Date:  2011-01-04       Impact factor: 4.473

5.  Destructive lymphadenopathy and T-lymphocyte activation in adult-onset Still's disease.

Authors:  M Koeller; H Kiener; I Simonitsch; M Aringer; C W Steiner; K Machold; W Graninger
Journal:  Br J Rheumatol       Date:  1995-10

6.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis.

Authors:  D Fishman; G Faulds; R Jeffery; V Mohamed-Ali; J S Yudkin; S Humphries; P Woo
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

7.  Adult-onset Still's disease. Clinical course and outcome.

Authors:  J J Cush; T A Medsger; W C Christy; D C Herbert; L A Cooperstein
Journal:  Arthritis Rheum       Date:  1987-02

8.  Th1 and Th17 cell subpopulations are enriched in the peripheral blood of patients with systemic juvenile idiopathic arthritis.

Authors:  Ebun Omoyinmi; Raja Hamaoui; Anne Pesenacker; Kiran Nistala; Halima Moncrieffe; Simona Ursu; Lucy R Wedderburn; Patricia Woo
Journal:  Rheumatology (Oxford)       Date:  2012-07-05       Impact factor: 7.580

9.  Novel IL10 gene family associations with systemic juvenile idiopathic arthritis.

Authors:  Mark S Fife; Ana Gutierrez; Emma M Ogilvie; Carmel J W Stock; Jane M Samuel; Wendy Thomson; Lisa F Mack; Cathryn M Lewis; Patricia Woo
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

Review 10.  NLRP3 inflammasome and its inhibitors: a review.

Authors:  Bo-Zong Shao; Zhe-Qi Xu; Bin-Ze Han; Ding-Feng Su; Chong Liu
Journal:  Front Pharmacol       Date:  2015-11-05       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.